The role of PPARγ in cardiovascular diseases

Physiological Research

Volumn 65, Issue , 2016, Pages S343-S363

  Kvandova M ^a   Majzunova M ^a   Dovinova I ^a  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Antioxidant response; Hypertension; Nitric oxide; Oxidative stress; PPAR ; Renin angiotensin system

Indexed keywords

INSULIN; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADRENERGIC SYSTEM; BIOLOGICAL MODEL; BLOOD PRESSURE; HUMAN; HYPERTENSION; MECHANOTRANSDUCTION; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; VASOCONSTRICTION; VASODILATATION;

BLOOD PRESSURE; HUMANS; HYPERTENSION; INSULIN; MECHANOTRANSDUCTION, CELLULAR; MODELS, CARDIOVASCULAR; NITRIC OXIDE; OXIDATIVE STRESS; PPAR GAMMA; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; VASOCONSTRICTION; VASODILATION; VASOMOTOR SYSTEM;

EID: 84997207098     PISSN: 08628408     EISSN: 18029973     Source Type: Journal    
DOI: 10.33549/physiolres.933439     Document Type: Review

References (173)

1. AGARWAL AK, GARG A: A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab 87: 408-411, 2002.
2. AHMADIAN M, DUNCAN RE, SUL HS: The skinny on fat: lipolysis and fatty acid utilization in adipocytes. Trends Endocrinol Metab 20: 424-428, 2009.
3. ANAN F, MASAKI T, FUKUNAGA N, TESHIMA Y, IWAO T, KANEDA K, UMENO Y, OKADA K, WAKASUGI K, YONEMOCHI H, ESHIMA N, SAIKAWA T, YOSHIMATSU H: Pioglitazone shift circadian rhythm of blood pressure from non-dipper to dipper type in type 2 diabetes mellitus. Eur J Clin Invest 37: 709-714, 2007.
4. APOSTOLIDIS A, WEISS RH: Divergence in the G-protein-coupled receptor mitogenic signalling pathway at the level of Raf kinase. Cell Signal 9: 439-445, 1997.
5. ARCE-ESQUIVEL AA, BUNKER AK, MIKUS CR, LAUGHLIN MH: Insulin resistance and endothelial dysfunction: Macro and microangiopathy. In: Type 2 Diabetes. MASUO K (ed), InTech, 2013, DOI: 10.5772/56475
6. ARMAGAN G, KESER A, ATALAYIN C, DAGCI T: Tideglusib protects neural stem cells against NMDA receptor overactivation. Pharmacol Rep 67: 823-831, 2015.
7. BARAK Y, NELSON MC, ONG ES, JONES YZ, RUIZ-LOZANO P, CHIEN KR, KODER A, EVANS RM: PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 4: 585-595, 1999.
8. BARROSO I, GURNELL M, CROWLEY VE, AGOSTINI M, SCHWABE JW, SOOS MA, MASLEN GL, WILLIAMS TD, LEWIS H, SCHAFER AJ, CHATTERJEE VK, O'RAHILLY S: Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402: 880-883, 1999.
9. BEENKEN A, MOHAMMADI M: The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8: 235-253, 2009.
10. BENKIRANE K, VIEL EC, AMIRI F, SCHIFFRIN EL: Peroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo. Hypertension 47: 102-108, 2006.
11. BERK BC, CORSON MA: Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. Circ Res 80: 607-616, 1997.
12. BUDZYN K, MARLEY PD, SOBEY CG: Targeting Rho and Rho-kinase in the treatment of cardiovascular disease. Trends Pharmacol Sci 27: 97-104, 2006.
13. BUCHANAN TA, MEEHAN WP, JENG YY, YANG D, CHAN TM, NADLER JL, SCOTT S, RUDE RK, HSUEH WA: Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest 96: 354-360, 1995.
14. BURRIS TP, BUSBY SA, GRIFFIN PR: Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity. Chem Biol 19: 51-59, 2012.
15. CALNEK DS, MAZZELLA L, ROSER S, ROMAN J, HART CM: Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 23: 52-57, 2003.
16. CAMP HS, TAFURI SR: Regulation of peroxisome proliferator-activated receptor gamma activity by mitogenactivated protein kinase. J Biol Chem 272: 10811-10816, 1997.
17. CAREY RM, WANG ZQ, SIRAGY HM: Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 35: 155-163, 2000.
18. CEOLOTTO G, GALLO A, PAPPARELLA I, FRANCO L, MURPHY E, IORI E, PAGNIN E, FADINI GP, ALBIERO M, SEMPLICINI A, AVOGARO A: Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-dependent mechanism. Arterioscler Thromb Vasc Biol 27: 2627-2633, 2007.
19. CERNECKA H, OCHODNICKA-MACKOVICOVA K, KUCEROVA D, KMECOVA J, NEMCEKOVA V, DOKA G, KYSELOVIC J, KRENEK P, OCHODNICKY P, KLIMAS J: Enalaprilat increases PPARβ/d expression, without influence on PPARα and PPARγ, and modulate cardiac function in sub-acute model of daunorubicininduced cardiomyopathy. Eur J Pharmacol 714: 472-477, 2013.
20. CHAN SH, WU KL, KUNG PS, CHAN JY: Oral intake of rosiglitazone promotes a central antihypertensive effect via upregulation of peroxisome proliferator-activated receptor-gamma and alleviation of oxidative stress in rostral ventrolateral medulla of spontaneously hypertensive rats. Hypertension 55: 1444-1453, 2010.
21. CHEN R, LIANG F, MORIYA J, YAMAKAWA JI, TAKAHASHI T, SHEN L, KAND T: Peroxisome proliferatoractivated receptors (PPARs) and their agonists for hypertension and heart failure: Are the reagents beneficial or harmful? Int J Cardiol 130: 131-139, 2008.
22. CHEN Y, JIMENEZ A R, MEDH JD: Identification and regulation of novel PPAR-gamma splice variants in human THP-1 macrophages. Biochim Biophys Acta 1759: 32-43, 2006.
23. CHEN Z, PENG IC, SUN W, SU MI, HSU PH, FU Y, ZHU Y, DEFEA K, PAN S, TSAI MD, SHYY JY: AMPactivated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Circ Res 104: 496-505, 2009.
24. CHENG P, ZHANG F, YU L, LIN X, HE L, LI X, LU X, YAN X, TAN Y, ZHANG C: Physiological and pharmacological roles of FGF21 in cardiovascular diseases. J Diabetes Res 2016: 1540267, 2016.
25. CHO HY, GLADWELL W, WANG X, CHORLEY B, BELL D, REDDY SP, KLEEBERGER SR: Nrf2-regulated PPARγ expression is critical to protection against acute lung injury in mice. Am J Respir Crit Care Med 182: 170-182, 2010.
26. CHRISTODOULIDES C, VIDAL-PUIG A: PPARs and adipocyte function. Mol Cell Endocrinol 318: 61-68, 2010.
27. CHUNG S S, KIM M, YOUN B S, LEE N S, PARK J W, LEE I K, LEE Y S, KIM J B, CHO Y M, LEE H K, PARK K S: Glutathione peroxidase 3 mediates the antioxidant effect of peroxisome proliferator-activated receptor gamma in human skeletal muscle cells. Mol Cell Biol 29: 20-30, 2009.
28. COMPE E, DRANE P, LAURENT C, DIDERICH K, BRAUN C, HOEIJMAKERS JH, EGLY JM: Dysregulation of the peroxisome proliferator-activated receptor target genes by XPD mutations. Mol Cell Biol 25: 6065-6076, 2005.
29. COPPS KD, WHITE MF: Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia 55: 2565-2582, 2012.
30. CROWLEY SD, COFFMAN TM: Recent advances involving the renin-angiotensin system. Exp Cell Res 318: 1049-1056, 2012.
31. DAMPNEY RA, TAN PS, SHERIFF MJ, FONTES MA, HORIUCHI J: Cardiovascular effects of angiotensin II in the rostral ventrolateral medulla: the push-pull hypothesis. Curr Hypertens Rep 9: 222-227, 2007.
32. DAS SK, CHAKRABARTI R: Role of PPAR in cardiovascular diseases. Recent Pat Cardiovasc Drug Discov 1: 193-209, 2006.
33. DEFRONZO RA, GUNNARSSON R, BJORKMAN O, OLSSON M, WAHREN J: Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest 76: 149-155, 1985.
34. DESVERGNE B, WAHLI W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20: 649-688, 1999.
35. DIEP QN, EL MABROUK M, COHN JS, ENDEMANN D, AMIRI F, VIRDIS A, NEVES MF, SCHIFFRIN EL: Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 105: 2296-2302, 2002.
36. DING G, FU M, QIN Q, LEWIS W, KIM HW, FUKAI T, BACANAMWO M, CHEN YE, SCHNEIDER MD, MANGELSDORF DJ, EVANS RM, YANG Q: Cardiac peroxisome proliferator-activated receptor gamma is essential in protecting cardiomyocytes from oxidative damage. Cardiovasc Res 76: 269-279, 2007.
37. DOBRIAN AD, SCHRIVER SD, KHRAIBI AA, PREWITT RL: Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension 43: 48-56, 2004.
38. DORMANDY JA, BETTERIDGE DJ, SCHERNTHANER G, PIRAGS V, NORGREN L, INVESTIGATORS P R: Impact of peripheral arterial disease in patients with diabetes-results from PROactive (PROactive 11). Atherosclerosis 202: 272-281, 2009.
39. DOVINOVA I, BARANCIK M, MAJZUNOVA M, ZORAD S, GAJDOSECHOVA L, GRESOVA L, CACANYIOVA S, KRISTEK F, BALIS P, CHAN JY: Effects of PPAR gamma agonist pioglitazone on redox-sensitive cellular signaling in young spontaneously hypertensive rats. PPAR Res 2013: 541871, 2013.
40. DOWNWARD J: Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10: 262-267, 1998.
41. DUAN SZ, IVASHCHENKO CY, RUSSELL MW, MILSTONE DS, MORTENSEN RM: Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ Res 97: 372-379, 2005.
42. DUAN SZ, IVASHCHENKO CY, WHITESALL SE, D'ALECY LG, DUQUAINE DC, BROSIUS FC, GONZALEZ FJ, VINSON C, PIERRE MA, MILSTONE DS, MORTENSEN RM: Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality. J Clin Invest 117: 812-822, 2007.
43. DUAN SZ, USHER MG, MORTENSEN RM: PPARs: the vasculature, inflammation and hypertension. Curr Opin Nephrol Hypertens 18: 128-133, 2009.
44. DUTCHAK PA, KATAFUCHI T, BOOKOUT AL, CHOI JH, YU RT, MANGELSDORF DJ, KLIEWER SA: Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell 148: 556-567, 2012.
45. EFRATI S, BERMAN S, ILGIYEAV E, AVERBUKH Z, WEISSGARTEN J: PPAR-gamma activation inhibits angiotensin II synthesis, apoptosis, and proliferation of mesangial cells from spontaneously hypertensive rats. Nephron Exp Nephrol 106: e107-e112, 2007.
46. ELAHI MM, KONG YX, MATATA BM: Oxidative stress as a mediator of cardiovascular disease. Oxid Med Cell Longev 2: 259-269, 2009.
47. FISHER FM, CHUI PC, ANTONELLIS PJ, BINA HA, KHARITONENKOV A, FLIER JS, MARATOS-FLIER E: Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59: 2781-2789, 2010.
48. FLEMING I, FISSLTHALER B, DIMMELER S, KEMP BE, BUSSE R: Phosphorylation of Thr(495) regulates Ca2+/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res 88: E68-E75, 2001.
49. FLEMING I, KOHLSTEDT K, BUSSE R: New fACEs to the renin-angiotensin system. Physiology (Bethesda) 20: 91-95, 2005.
50. FRANKE TF, KAPLAN DR, CANTLEY LC, TOKER A: Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 275: 665-668, 1997.
51. FRUCHART JC, STAELS B, DURIEZ P: The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 3: 83-92, 2001.
52. FU Z, GILBERT ER, LIU D: Regulation of insulin synthesis and secretion and pancreatic beta-cell dysfunction in diabetes. Curr Diabetes Rev 9: 25-53, 2013.
53. FUKUDA N, HU WY, TENG J, CHIKARA S, NAKAYAMA M, KISHIOKA H, KANMATSUSE K: Troglitazone inhibits growth and improves insulin signaling by suppression of angiotensin II action in vascular smooth muscle cells from spontaneously hypertensive rats. Atherosclerosis 163: 229-239, 2002.
54. GARDLIK R, DOVINOVA I, CHAN J: Approaches in gene therapy of cancer and cardiovascular diseases In: Gene Therapy Applications. KANG C (ed), In Tech, 2011. DOI: 10.5772/18280
55. GINGRAS AC, KENNEDY SG, O'LEARY MA, SONENBERG N, HAY N: 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev 12: 502-513, 1998.
56. GOETZE S, XI XP, GRAF K, FLECK E, HSUEH WA, LAW RE: Troglitazone inhibits angiotensin II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells. FEBS Lett 452: 277-282, 1999.
57. GOSSE P: A review of telmisartan in the treatment of hypertension: blood pressure control in the early morning hours. Vasc Health Risk Manag 2: 195-201, 2006.
58. GOVERS R, RABELINK TJ: Cellular regulation of endothelial nitric oxide synthase. Am J Physiol Renal Physiol 280: F193-F206, 2001.
59. HANKE S, MANN M: The phosphotyrosine interactome of the insulin receptor family and its substrates IRS-1 and IRS-2. Mol Cell Proteomics 8: 519-534, 2009.
60. HARRIS DM, COHN HI, PESANT S, ECKHART AD: GPCR signalling in hypertension: role of GRKs. Clin Sci (Lond) 115: 79-89, 2008.
61. HAUSER S, ADELMANT G, SARRAF P, WRIGHT HM, MUELLER E, SPIEGELMAN BM: Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. J Biol Chem 275: 18527-18533, 2000.
62. HEGELE RA, CAO H, FRANKOWSKI C, MATHEWS ST, LEFF T: PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes 51: 3586-3590, 2002.
63. HU E, KIM JB, SARRAF P, SPIEGELMAN BM: Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science 274: 2100-2103, 1996.
64. HU L, ZHU DN, YU Z, WANG JQ, SUN ZJ, YAO T: Expression of angiotensin II type 1 (AT1) receptor in the rostral ventrolateral medulla in rats. J Appl Physiol 92: 2153-2161, 2002.
65. HUANG J, TABBI-ANNENI I, GUNDA V, WANG L: Transcription factor Nrf2 regulates SHP and lipogenic gene expression in hepatic lipid metabolism. Am J Physiol Gastrointest Liver Physiol 299: G1211-G1221, 2010.
66. HUR W, GRAY NS: Small molecule modulators of antioxidant response pathway. Curr Opin Chem Biol 15: 162-173, 2011.
67. HWANG J, KLEINHENZ DJ, LASSEGUE B, GRIENDLING KK, DIKALOV S, HART CM: Peroxisome proliferatoractivated receptor-gamma ligands regulate endothelial membrane superoxide production. Am J Physiol Cell Physiol 288: C899-C905, 2005.
68. IANKOVA I, PETERSEN RK, ANNICOTTE JS, CHAVEY C, HANSEN JB, KRATCHMAROVA I, SARRUF D, BENKIRANE M, KRISTIANSEN K, FAJAS L: Peroxisome proliferator-activated receptor gamma recruits the positive transcription elongation factor b complex to activate transcription and promote adipogenesis. Mol Endocrinol 20: 1494-1505, 2006.
69. IMAYAMA I, ICHIKI T, INANAGA K, OHTSUBO H, FUKUYAMA K, ONO H, HASHIGUCHI Y, SUNAGAWA K: Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferatoractivated receptor gamma. Cardiovasc Res 72: 184-190, 2006.
70. ISHII T, ITOH K, YAMAMOTO M: Roles of Nrf2 in activation of antioxidant enzyme genes via antioxidant responsive elements. Methods Enzymol 348: 182-190, 2002.
71. ISHII T, ITOH K, RUIZ E, LEAKE D S, UNOKI H, YAMAMOTO M, MANN GE: Role of Nrf2 in the regulation of CD36 and stress protein expression in murine macrophages: activation by oxidatively modified LDL and 4-hydroxynonenal. Circ Res 94: 609-616, 2004.
72. ISSEMANN I, GREEN S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347: 645-650, 1990.
73. JAIN AK, JAISWAL AK: Phosphorylation of tyrosine 568 controls nuclear export of Nrf2. J Biol Chem 281: 12132-12142, 2006.
74. JONKER JW, SUH JM, ATKINS AR, AHMADIAN M, LI P, WHYTE J, HE M, JUGUILON H, YIN Y Q, PHILLIPS CT, YU RT, OLEFSKY JM, HENRY RR, DOWNES M, EVANS RM: A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature 485: 391-394, 2012.
75. JUST A, WHITTEN CL, ARENDSHORST WJ: Reactive oxygen species participate in acute renal vasoconstrictor responses induced by ETA and ETB receptors. Am J Physiol Renal Physiol 294: F719-F728, 2008.
76. KANNINEN K, WHITE AR, KOISTINAHO J, MALM T: Targeting glycogen synthase kinase-3beta for therapeutic benefit against oxidative stress in alzheimer's disease: involvement of the Nrf2-ARE pathway. Int J Alzheimers Dis 2011: 985085, 2011.
77. KIM EK, CHOI EJ: Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 1802: 396-405, 2010.
78. KIM TH, KIM MY, JO SH, PARK JM, AHN YH: Modulation of the transcriptional activity of peroxisome proliferatoractivated receptor gamma by protein-protein interactions and post-translational modifications. Yonsei Med J 54: 545-559, 2013.
79. KIMURA Y, HIROOKA Y, SAGARA Y, ITO K, KISHI T, SHIMOKAWA H, TAKESHITA A, SUNAGAWA K: Overexpression of inducible nitric oxide synthase in rostral ventrolateral medulla causes hypertension and sympathoexcitation via an increase in oxidative stress. Circ Res 96: 252-260, 2005.
80. KISS M, CZIMMERER Z, NAGY L: The role of lipid-activated nuclear receptors in shaping macrophage and dendritic cell function: From physiology to pathology. J Allergy Clin Immunol 132: 264-286, 2013.
81. KITAMURA T, OGAWA W, SAKAUE H, HINO Y, KURODA S, TAKATA M, MATSUMOTO M, MAEDA T, KONISHI H, KIKKAWA U, KASUGA M: Requirement for activation of the serine-threonine kinase Akt (protein kinase B) in insulin stimulation of protein synthesis but not of glucose transport. Mol Cell Biol 18: 3708-3717, 1998.
82. KLIPPEL A, KAVANAUGH WM, POT D, WILLIAMS LT: A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain. Mol Cell Biol 17: 338-344, 1997.
83. KOBAYASHI N, OHNO T, YOSHIDA K, FUKUSHIMA H, MAMADA Y, NOMURA M, HIRATA H, MACHIDA Y, SHINODA M, SUZUKI N, MATSUOKA H: Cardioprotective mechanism of telmisartan via PPARgamma-eNOS pathway in Dahl salt-sensitive hypertensive rats. Am J Hypertens 21: 576-581, 2008.
84. KOBAYASHI T, TAGUCHI K, YASUHIRO T, MATSUMOTO T, KAMATA K: Impairment of PI3-K/Akt pathway underlies attenuated endothelial function in aorta of type 2 diabetic mouse model. Hypertension 44: 956-962, 2004.
85. KOBORI H, NANGAKU M, NAVAR LG, NISHIYAMA A: The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 59: 251-287, 2007.
86. KOH KK, QUON MJ, HAN SH, AHN JY, JIN DK, KIM HS, KIM DS, SHIN EK: Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 45: 1088-1093, 2005.
87. KOH KK, QUON MJ, HAN SH, CHUNG WJ, AHN JY, KIM JA, LEE Y, SHIN EK: Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. Diabetes Care 29: 195-201, 2006.
88. KOHLROSER J, MATHAI J, REICHHELD J, BANNER BF, BONKOVSKY HL: Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol 95: 272-276, 2000.
89. KRISHNASWAMI A, RAVI-KUMAR S, LEWIS JM: Thiazolidinediones: a 2010 perspective. Perm J 14: 64-72, 2010.
90. KRONKE G, KADL A, IKONOMU E, BLUML S, FURNKRANZ A, SAREMBOCK IJ, BOCHKOV VN, EXNER M, BINDER BR, LEITINGER N: Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol 27: 1276-1282, 2007.
91. KUBOTA T, KUBOTA N, KUMAGAI H, YAMAGUCHI S, KOZONO H, TAKAHASHI T, INOUE M, ITOH S, TAKAMOTO I, SASAKO T, KUMAGAI K, KAWAI T, HASHIMOTO S, KOBAYASHI T, SATO M, TOKUYAMA K, NISHIMURA S, TSUNODA M, IDE T, MURAKAMI K, YAMAZAKI T, EZAKI O, KAWAMURA K, MASUDA H, MOROI M, SUGI K, OIKE Y, SHIMOKAWA H, YANAGIHARA N, TSUTSUI M, TERAUCHI Y, TOBE K, NAGAI R, KAMATA K, INOUE K, KODAMA T, UEKI K, KADOWAKI T: Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab 13: 294-307, 2011.
92. LAI EY, SOLIS G, LUO Z, CARLSTROM M, SANDBERG K, HOLLAND S, WELLSTEIN A, WELCH WJ, WILCOX CS: p47(phox) is required for afferent arteriolar contractile responses to angiotensin II and perfusion pressure in mice. Hypertension 59: 415-420, 2012.
93. LEONARDINI A, LAVIOLA L, PERRINI S, NATALICCHIO A, GIORGINO F: Cross-talk between PPARgamma and insulin signaling and modulation of insulin sensitivity. PPAR Res 2009: 818945, 2009.
94. LI J, WANG N: Peroxisome proliferator-activated receptor-gamma in vascular biology. Cardiovasc Hematol Disord Drug Targets 7: 109-117, 2007.
95. LI R, ZHANG H, WANG W, WANG X, HUANG Y, HUANG C, GAO F: Vascular insulin resistance in prehypertensive rats: role of PI3-kinase/Akt/eNOS signaling. Eur J Pharmacol 628: 140-147, 2010.
96. LILLIOJA S, YOUNG AA, CULTER CL, IVY JL, ABBOTT WG, ZAWADZKI JK, YKI-JARVINEN H, CHRISTIN L, SECOMB TW, BOGARDUS C: Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J Clin Invest 80: 415-424, 1987.
97. LINDI VI, UUSITUPA MI, LINDSTROM J, LOUHERANTA A, ERIKSSON JG, VALLE TT, HAMALAINEN H, ILANNE-PARIKKA P, KEINANEN-KIUKAANNIEMI S, LAAKSO M, TUOMILEHTO J, FINNISH DIABETES PREVENTION STUDY: Association of the Pro12Ala polymorphism in the PPAR-γ2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes 51: 2581-2586, 2002.
98. MAJZUNOVA M, DOVINOVA I, BARANCIK M, CHAN JY: Redox signaling in pathophysiology of hypertension. J Biomed Sci 20: 69, 2013.
99. MITCHELL JA, ALI F, BAILEY L, MORENO L, HARRINGTON LS: Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium. Exp Physiol 93: 141-147, 2008.
100. MONTANEZ JE, PETERS JM, CORRELL JB, GONZALEZ FJ, PATTERSON AD: Metabolomics: an essential tool to understand the function of peroxisome proliferator-activated receptor alpha. Toxicol Pathol 41: 410-418, 2013.
101. MONTEZANO AC, TOUYZ RM: Reactive oxygen species, vascular Noxs, and hypertension: focus on translational and clinical research. Antioxid Redox Signal 20: 164-182, 2014.
102. 12->Ala substitution in PPAR-γ is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 50: 891-894, 2001.
103. MOUNT PF, KEMP BE, POWER DA: Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J Mol Cell Cardiol 42: 271-279, 2007.
104. NAGAO S, YAMAGUCHI T: PPAR-gamma agonists in polycystic kidney disease with frequent development of cardiovascular disorders. Curr Mol Pharmacol 5: 292-300, 2012.
105. NAKAMURA T, USHIYAMA C, SHIMADA N, HAYASHI K, EBIHARA I, KOIDE H: Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications 14: 250-254, 2000.
106. NGUYEN T, NIOI P, PICKETT CB: The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 284: 13291-13295, 2009.
107. NISHIJO N, SUGIYAMA F, KIMOTO K, TANIGUCHI K, MURAKAMI K, SUZUKI S, FUKAMIZU A, YAGAMI K: Salt-sensitive aortic aneurysm and rupture in hypertensive transgenic mice that overproduce angiotensin II. Lab Invest 78: 1059-1066, 1998.
108. NISSEN SE, WOLSKI K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471, 2007.
109. NOHRIA A, GRUNERT ME, RIKITAKE Y, NOMA K, PRSIC A, GANZ P, LIAO J K, CREAGER MA: Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res 99: 1426-1432, 2006.
110. OGIHARA T, SHIN BC, ANAI M, KATAGIRI H, INUKAI K, FUNAKI M, FUKUSHIMA Y, ISHIHARA H, TAKATA K, KIKUCHI M, YAZAKI Y, OKA Y, ASANO T: Insulin receptor substrate (IRS)-2 is dephosphorylated more rapidly than IRS-1 via its association with phosphatidylinositol 3-kinase in skeletal muscle cells. J Biol Chem 272: 12868-12873, 1997.
111. OLIVEIRA JM, REBUFFAT SA, GASA R, GOMIS R: Targeting type 2 diabetes: lessons from a knockout model of insulin receptor substrate 2. Can J Physiol Pharmacol 92: 613-620, 2014.
112. OSTGREN CJ, LINDBLAD U, MELANDER O, MELANDER A, GROOP L, RASTAM L: Peroxisome proliferatoractivated receptor-γ Pro12Ala polymorphism and the association with blood pressure in type 2 diabetes: Skaraborg Hypertension and Diabetes Project. J Hypertens 21: 1657-1662, 2003.
113. OYEKAN A: PPARs and their effects on the cardiovascular system. Clin Exp Hypertens 33: 287-293, 2011.
114. PARK EY, CHO IJ, KIM SG: Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-gamma and retinoid X receptor heterodimer. Cancer Res 64: 3701-3713, 2004.
115. PASCUAL G, FONG AL, OGAWA S, GAMLIEL A, LI AC, PERISSI V, ROSE DW, WILLSON TM, ROSENFELD MG, GLASS CK: A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437: 759-763, 2005.
116. PETERS SL, MATHY MJ, PFAFFENDORF M, VAN ZWIETEN PA: Reactive oxygen species-induced aortic vasoconstriction and deterioration of functional integrity. Naunyn-Schmiedebergs Arch Pharmacol 361: 127-133, 2000.
117. POLIKANDRIOTIS JA, MAZZELLA LJ, RUPNOW HL, HART CM: Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms. Arterioscler Thromb Vasc Biol 25: 1810-1816, 2005.
118. POLVANI S, TAROCCHI M, GALLI A: PPARgamma and oxidative stress: con(beta) catenating NRF2 and FOXO. PPAR Res 2012: 641087, 2012.
119. RAJI A, SEELY EW, BEKINS SA, WILLIAMS GH, SIMONSON DC: Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 26: 172-178, 2003.
120. REICHARD JF, MOTZ GT, PUGA A: Heme oxygenase-1 induction by NRF2 requires inactivation of the transcriptional repressor BACH1. Nucleic Acids Res 35: 7074-7086, 2007.
121. REN Y, SUN C, SUN Y, TAN H, WU Y, CUI B, WU Z: PPAR gamma protects cardiomyocytes against oxidative stress and apoptosis via Bcl-2 upregulation. Vascul Pharmacol 51: 169-174, 2009.
122. ROBINSON MJ, COBB MH: Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9: 180-186, 1997.
123. RODRIGO R, GONZALEZ J, PAOLETTO F: The role of oxidative stress in the pathophysiology of hypertension. Hypertens Res 34: 431-440, 2011.
124. RODRIGUES-FERREIRA S, NAHMIAS C: G-protein coupled receptors of the renin-angiotensin system: new targets against breast cancer? Front Pharmacol 6: 24, 2015.
125. ROSZER T, RICOTE M: PPARs in the renal regulation of systemic blood pressure. PPAR Res 2010: 698730, 2010.
126. SANCHEZ RA, MASNATTA LD, PESINEY C, FISCHER P, RAMIREZ AJ: Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives. J Hypertens 26: 2393-2398, 2008.
127. SANTOS RA, FERREIRA AJ, VERANO-BRAGA T, BADER M: Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J Endocrinol 216: R1-R17, 2013.
128. SARABIA V, RAMLAL T, KLIP A: Glucose uptake in human and animal muscle cells in culture. Biochem Cell Biol 68: 536-542, 1990.
129. SARABIA V, LAM L, BURDETT E, LEITER LA, KLIP A: Glucose transport in human skeletal muscle cells in culture. Stimulation by insulin and metformin. J Clin Invest 90: 1386-1395, 1992.
130. SCHEID MP, HUBER M, DAMEN JE, HUGHES M, KANG V, NEILSEN P, PRESTWICH GD, KRYSTAL G, DURONIO V: Phosphatidylinositol (3,4,5)P3 is essential but not sufficient for protein kinase B (PKB) activation; phosphatidylinositol (3,4)P2 is required for PKB phosphorylation at Ser-473: studies using cells from SH2-containing inositol-5-phosphatase knockout mice. J Biol Chem 277: 9027-9035, 2002.
131. SCHIEFFER B, DREXLER H, LING BN, MARRERO MB: G protein-coupled receptors control vascular smooth muscle cell proliferation via pp60c-src and p21ras. Am J Physiol 272: C2019-C2030, 1997.
132. SEMPLE RK, MEIRHAEGHE A, VIDAL-PUIG AJ, SCHWABE JW, WIGGINS D, GIBBONS GF, GURNELL M, CHATTERJEE VK, O'RAHILLY S: A dominant negative human peroxisome proliferator-activated receptor (PPAR)a is a constitutive transcriptional corepressor and inhibits signaling through all PPAR isoforms. Endocrinology 146: 1871-1882, 2005.
133. SHARGORODSKY M, WAINSTEIN J, GAVISH D, LEIBOVITZ E, MATAS Z, ZIMLICHMAN R: Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus. Am J Hypertens 16: 617-622, 2003.
134. SHARMA MD, GARBER AJ, FARMER JA: Role of insulin signaling in maintaining energy homeostasis. Endocr Pract 14: 373-380, 2008.
135. SHIMIZU M, YAMASHITA D, YAMAGUCHI T, HIROSE F, OSUMI T: Aspects of the regulatory mechanisms of PPAR functions: analysis of a bidirectional response element and regulation by sumoylation. Mol Cell Biochem 286: 33-42, 2006.
136. SIES H: Biological redox systems and oxidative stress. Cell Mol Life Sci 64: 2181-2188, 2007.
137. SONG J, LIU H, RESSOM HW, TIWARI S, ECELBARGER CM: Chronic rosiglitazone therapy normalizes expression of ACE1, SCD1 and other genes in the kidney of obese Zucker rats as determined by microarray analysis. Exp Clin Endocrinol Diabetes 116: 315-325, 2008.
138. SORRENTINO SA, BAHLMANN FH, BESLER C, MULLER M, SCHULZ S, KIRCHHOFF N, DOERRIES C, HORVATH T, LIMBOURG A, LIMBOURG F, FLISER D, HALLER H, DREXLER H, LANDMESSER U: Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 116: 163-173, 2007.
139. SUGAWARA A, URUNO A, KUDO M, MATSUDA K, YANG C W, ITO S: Effects of PPARgamma on hypertension, atherosclerosis, and chronic kidney disease. Endocr J 57: 847-852, 2010.
140. SUN K, SCHERER PE: The PPARgamma-FGF1 axis: an unexpected mediator of adipose tissue homeostasis. Cell Res 22: 1416-1418, 2012.
141. TAGAMI T, YAMAMOTO H, MORIYAMA K, SAWAI K, USUI T, SHIMATSU A, NARUSE M: A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones. Endocrinology 150: 862-870, 2009.
142. TAIN YL, HSU CN, CHAN JY: PPARs link early life nutritional insults to later programmed hypertension and metabolic syndrome. Int J Mol Sci 17: 20, 2016. doi:10.3390/ijms17010020
143. TAKAI S, JIN D, KIMURA M, KIRIMURA K, SAKONJO H, TANAKA K, MIYAZAKI M: Inhibition of vascular angiotensin-converting enzyme by telmisartan via the peroxisome proliferator-activated receptor gamma agonistic property in rats. Hypertens Res 30: 1231-1237, 2007.
144. TAKEDA K, ICHIKI T, TOKUNOU T, FUNAKOSHI Y, IINO N, HIRANO K, KANAIDE H, TAKESHITA A: Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation 102: 1834-1839, 2000.
145. TANIGUCHI A, FUKUSHIMA M, SAKAI M, TOKUYAMA K, NAGATA I, FUKUNAGA A, KISHIMOTO H, DOI K, YAMASHITA Y, MATSUURA T, KITATANI N, OKUMURA T, NAGASAKA S, NAKAISHI S, NAKAI Y: Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients. Metabolism 50: 477-480, 2001.
146. THOMAS SM, BRUGGE JS: Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13: 513-609, 1997.
147. TOUYZ RM: Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II. Curr Opin Nephrol Hypertens 14: 125-131, 2005.
148. TOUYZ RM, BRIONES AM: Reactive oxygen species and vascular biology: Implications in human hypertension. Hypertens Res 34: 5-14, 2011.
149. TOUYZ RM, SCHIFFRIN EL: Ang II-stimulated superoxide production is mediated via phospholipase D in human vascular smooth muscle cells. Hypertension 34: 976-982, 1999.
150. TOUYZ RM, SCHIFFRIN EL: Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 52: 639-672, 2000.
151. TOUYZ RM, TABET F, SCHIFFRIN EL: Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. Clin Exp Pharmacol Physiol 30: 860-866, 2003.
152. UNGER T, STOPPELHAAR M: Rationale for double renin-angiotensin-aldosterone system blockade. Am J Cardiol 100: 25J-31J, 2007.
153. USHIO-FUKAI M, ALEXANDER RW, AKERS M, YIN Q, FUJIO Y, WALSH K, GRIENDLING KK: Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. J Biol Chem 274: 22699-22704, 1999.
154. VAN BEEKUM O, FLESKENS V, KALKHOVEN E: Posttranslational modifications of PPAR-gamma: fine-tuning the metabolic master regulator. Obesity (Silver Spring) 17: 213-219, 2009.
155. VANDEWALLE B, MOERMAN E, LEFEBVRE B, DEFRANCE F, GMYR V, LUKOWIAK B, KERR CONTE J, PATTOU F: PPARgamma-dependent and-independent effects of rosiglitazone on lipotoxic human pancreatic islets. Biochem Biophys Res Commun 366: 1096-1101, 2008.
156. VARGA T, CZIMMERER Z, NAGY L: PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta 1812: 1007-1022, 2011.
157. WAKINO S, KINTSCHER U, KIM S, JACKSON S, YIN F, NAGPAL S, CHANDRARATNA RA, HSUEH WA, LAW RE: Retinoids inhibit proliferation of human coronary smooth muscle cells by modulating cell cycle regulators. Arterioscler Thromb Vasc Biol 21: 746-751, 2001.
158. WAKINO S, HAYASHI K, KANDA T, TATEMATSU S, HOMMA K, YOSHIOKA K, TAKAMATSU I, SARUTA T: Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2. Circ Res 95: e45-e55, 2004.
159. WANG D, CHABRASHVILI T, WILCOX CS: Enhanced contractility of renal afferent arterioles from angiotensininfused rabbits: roles of oxidative stress, thromboxane prostanoid receptors, and endothelium. Circ Res 94: 1436-1442, 2004.
160. WANG N, YANG G, JIA Z, ZHANG H, AOYAGI T, SOODVILAI S, SYMONS JD, SCHNERMANN JB, GONZALEZ FJ, LITWIN SE, YANG T: Vascular PPARgamma controls circadian variation in blood pressure and heart rate through Bmal1. Cell Metab 8: 482-491, 2008.
161. WANG X, WANG Z, LIU JZ, HU JX, CHEN HL, LI WL, HAI CX: Double antioxidant activities of rosiglitazone against high glucose-induced oxidative stress in hepatocyte. Toxicol In Vitro 25: 839-847, 2011.
162. WATERS SB, PESSIN JE: Insulin receptor substrate 1 and 2 (IRS1 and IRS2): what a tangled web we weave. Trends Cell Biol 6: 1-4, 1996.
163. WELCH WJ, OTT CE, GUTHRIE GP JR, KOTCHEN TA: Mechanism of increased renin release in the adrenalectomized rat. Adrenal insufficiency and renin. Hypertension 5 (Suppl I): I47-I52, 1983.
164. WILLSON TM, COBB JE, COWAN DJ, WIETHE RW, CORREA ID, PRAKASH SR, BECK KD, MOORE LB, KLIEWER SA, LEHMANN JM: The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39: 665-668, 1996.
165. WONG WT, TIAN XY, XU A, YU J, LAU C W, HOO RL, WANG Y, LEE VW, LAM KS, VANHOUTTE PM, HUANG Y: Adiponectin is required for PPARgamma-mediated improvement of endothelial function in diabetic mice. Cell Metab 14: 104-115, 2011.
166. WU KL, CHAO YM, TSAY SJ, CHEN CH, CHAN SH, DOVINOVA I, CHAN J Y: Role of nitric oxide synthase uncoupling at rostral ventrolateral medulla in redox-sensitive hypertension associated with metabolic syndrome. Hypertension 64: 815-824, 2014.
167. WU L, WANG R, DE CHAMPLAIN J, WILSON TW: Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats. Am J Hypertens 17: 749-756, 2004.
168. 2+ release modulates endothelial nitric-oxide synthase via extracellular signal-regulated kinase (ERK) 1/2-mediated serine 635 phosphorylation. J Biol Chem 286: 20100-20108, 2011.
169. YU J, ZHANG Z, LI Z, FENG X, HE L, LIU S, MAO J, WANG G, WANG X: Peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist improves coronary artery endothelial function in diabetic patients with coronary artery disease. J Int Med Res 38: 86-94, 2010.
170. ZHANG B, BERGER J, ZHOU G, ELBRECHT A, BISWAS S, WHITE-CARRINGTON S, SZALKOWSKI D, MOLLER DE: Insulin-and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma. J Biol Chem 271: 31771-31774, 1996.
171. ZHAO Y, PATZER A, HERDEGEN T, GOHLKE P, CULMAN J: Activation of cerebral peroxisome proliferatoractivated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats. FASEB J 20: 1162-1175, 2006.
172. ZHUANG Z, ZHAO X, WU Y, HUANG R, ZHU L, ZHANG Y, SHI J: The anti-apoptotic effect of PI3K-Akt signaling pathway after subarachnoid hemorrhage in rats. Ann Clin Lab Sci 41: 364-372, 2011.
173. ZICHA J, DOBESOVA Z, BEHULIAK M, PINTEROVA M, KUNES J, VANECKOVA I: Nifedipine-sensitive blood pressure component in hypertensive models characterized by high activity of either sympathetic nervous system or renin-angiotensin system. Physiol Res 63: 13-26, 2014.